Abstract: High-throughput screening technologies such as microarrays and 2D electrophoresis are powerful analytical tools particularly suited to investigating the pathologies of complex diseases. Schizophrenia is now widely recognised as a complex disorder resulting from the interplay between genetic predisposition to the illness and the effects of yet to be identified environmental factors. Based the hypothesis that the outcome of the interaction between genetic predisposition and environmental factors act to produce changes in protein expression in the CNS to cause schizophrenia, a number of studies have used postmortem CNS and highthroughput screening technologies to identify potential pathological processes that might be involved in the pathology of the disorder. This review attempts to place the current findings on gene and protein expression data in postmortem CNS from subjects with schizophrenia into a perspective that allows hypotheses on the cause of the disorder to be formulated.
There is a growing consensus that schizophrenia manifests in individuals who have a complex genetic predisposition, following interactions with yet to be identified environmental factors [1] . Building on this hypothesis, it would be predicted that the symptoms of schizophrenia result from the summed effects of primary genetic abnormalities and the impact of environmental factors on gene expression in the CNS. In such a milieu, the use of available genetic analysis techniques to identify the susceptibility genes for schizophrenia would be extremely difficult, which could be why such approaches have yet to generate strong candidate genes for the disorder [2] .
HIGH-THROUGHPUT SCREENING OF GENE EXPRESSION IN SCHIZOPHRENIA
It is now over a decade since the first attempts to use high-throughput screening technology to identify altered gene expression in postmortem CNS from subjects with psychiatric illness [7, 8] . This first approach relied upon the in vitro translation of poly(A+) mRNA using a cell-free reticulocyte-lysate system followed by 2D electrophoresis analysis of translated proteins. Despite finding proteins that were present at different concentrations, presumably because of changes in levels of mRNA in tissue from the subjects with schizophrenia and depression that would be needed to drive the differential production of proteins in the cell free system, no genes appear to have been positively identified as being differentially expressed in the CNS from subjects with psychiatric disorders.
Postmortem CNS research on schizophrenia is experiencing a resurgence based on the premise that a footprint of the pathology of the disorder can be identified after death ( Fig. 1) and because new technologies are now available that allow the study of complex biological processes. The most utilised of these technologies involve the simultaneous measurement of levels of mRNA from thousands of genes in critical CNS regions from subjects with the disorder [3] . More recently, equally powerful tools have been refined to the point where the study of the human proteome in postmortem CNS is feasible [4] . The impact of these technologies, in conjunction with the unraveling of the human genome [5, 6] , is changing perceptions of the likely causes of the disorder. It is, therefore, timely to focus a review on the impact of high-throughput screening of gene and protein expression on our understanding of the pathology of schizophrenia.
The Role of Mitochondrial Proteins in the Pathology of Schizophrenia
The next approach to determine genes that were differentially expressed in the CNS of subjects with schizophrenia involved the use of sequential differential hybridisation [9] . Using this technique, 5 cDNA clones were identified that appeared to be differentially expressed in the frontal cortex from subjects with schizophrenia; all these clones were derived from mitochondrial DNA sequences. One clone was identified as cytochrome oxidase II (COX II) and a further study using dot-blot analysis of mRNA confirmed increased expression in the cortex of subjects with the disorder. In a follow up study, increased levels of COX II expression were again identified as being up-regulated in postmortem CNS from subjects with schizophrenia and, in addition, expression of the gene was decreased in the cortex of rats that had received α-flupenthixol [10] . These data are consistent with a role for altered expression of COX II in the pathology of schizophrenia but, as yet, the role of COX II in causing the disorder remains unknown.
with schizophrenia who have peripheral insulin resistance, this could be a reason to not treat with antipsychotic drugs that may increase the likelihood of individuals developing frank diabetes [14, 15] . A more recent study using microarrays, a technology that has accelerated the screening of gene expression in schizophrenia, reported that the expression of cytochrome c oxidase subunit IV was increased in the cerebellum, but not frontal cortex, from subjects with schizophrenia [11] . By contrast, the same study reported P450 (cytochrome) oxidoreductase expression to be decreased in the prefrontal cortex, but not cerebellum, from subjects with the disorder. Finally, another microarray study reported altered levels of expression of genes in the malate shuttle (glutamicoxaloacetic transaminase 2, mitochondrial and malate dehydrogenase 1, NAD (soluble)) [12] . All these data support the hypothesis that changes in metabolic pathways are important in the pathology of schizophrenia but further work is required to fully understand the impact of such changes on CNS function.
Presynaptic Function in Schizophrenia
In the first reported study using microarray technology and postmortem CNS from subjects with schizophrenia it was suggested that genes involved in the regulation of presynaptic function were particularly affected in the prefrontal cortex from subjects with schizophrenia [16] . The most consistent finding in this study was decreased expression of N-ethylmaleimide sensitive factor (NSF) and synapsin II (SYN2) in the tissue from subjects with the disorder. The subsequent demonstration of an up-regulation in the striatal expression of SYN2 in rats that had received haloperidol [17] and a positive association between SYN2 genotype and schizophrenia [18] makes the SYN2 gene an important candidate in playing a role in the pathology of schizophrenia. However, a failure to show any change in the levels of NSF or SYN2 mRNA or protein in the prefrontal cortex from a different cohort of subjects with schizophrenia [19] indicates that further investigations are required to better understand the extent to which these genes are implicated in the pathology of schizophrenia.
With a growing body of evidence suggesting that CNS metabolic pathways are affected in schizophrenia, it is intriguing to postulate whether these abnormalities, if present in the periphery, contribute to the increased level of insulin resistance that has long been recognised in some individuals with schizophrenia [13] . If there are individuals The hypothesis that there are changes in presynaptic functioning associated with schizophrenia is supported by another microarray study that showed decreases in the expression of the presynaptic proteins synaptophysin, synaptosomal-associated protein (SNAP) 23 and SNAP 25 using single-microdissected neurons from the entorhinal cortex from subjects with the disorder [20] . These data add to some, but not all, earlier studies that suggest there might be regionally specific changes in SNAP 25 and synaptophysin in the CNS of subjects with schizophrenia ( Table 1 ). The study of these presynaptic proteins also shows that there is dissociation between changes in levels of mRNA and changes in resulting protein in the CNS from subjects with schizophrenia.
using in situ hybridisation on schizophrenic tissue and RGS 4 expression levels were not altered in the prefrontal cortex of subjects with depression. The absence of changed levels of mRNA for RGS 4 in tissue from subjects with depression adds a degree of disease specificity to the findings in schizophrenia. Finally, the absence of change in levels of mRNA in cortex from monkeys treated with haloperidol suggested any changes in the CNS from subjects with schizophrenia were not simply an effect of antipsychotic drug treatment prior to death.
The data from the postmortem study implicating RGS 4 in the pathology has now been strengthened by four studies suggesting that specific genotypes for RGS 4 give an increased risk of developing schizophrenia [22] [23] [24] [25] . Thus, RGS 4 is currently a strong candidate gene that is implicated in the pathology of schizophrenia. RGS 4 has been shown to be critical in GTP hydrolysis [26] , to undergo dynamic changes in expression during neurodevelopment [27] and to be regulated by neurotransmitters such as dopamine [28] . Hence, there are many outcomes from dysregulation of RGS 4 expression which could result in the symptoms of schizophrenia. Therefore, it is now critical to understand the mechanisms by which this important signal transduction protein could be involved in the pathology of the disorder.
RGS 4 Signalling Pathway in Schizophrenia
In a study of signal transduction pathways, the group that reported changes in proteins which regulate presynaptic function also showed a decrease in the expression of the regulator of G-protein signaling (RGS) 4 in the prefrontal cortex from subjects with schizophrenia [21] . Significantly, the level of expression of 6 other RGS proteins (RGS 2, 3, 5, 9, 12 and 13) were not altered in the same tissue. The finding of decreased levels of RGS 4 mRNA were confirmed Fig. (2) . The potential impact of changes in gene and protein expression identified using high throughput screening techniques and postmortem CNS on current understanding of the pathology of schizophrenia. The schema shows how changes in both neuregulin related pathways and presynaptic function could have profound impact on human CNS function.
Another study in the dorsolateral prefrontal cortex reported increased expression of RGS 7 as part of a study that showed that the expression of 89 genes was altered in tissue from subjects with schizophrenia [29] . These data may indicate that changes in the RGS protein family in schizophrenia are not restricted to RGS 4.
A Role for Apolipoproteins in the Pathology of Schizophrenia
One microarray study showed an increase in the expression of apolipoprotein L1 (apo L1) in tissue from subjects with schizophrenia but not from subjects with bipolar disorder [47] . This study went on to use real-time PCR and tissue from another brain collection to show that the expression of apoL1 and apoL4 was increased in the prefrontal cortex from subjects with schizophrenia whereas apoL2 was increased in schizophrenia and bipolar disorder. Thus, the expression of three of the six members of the apoL family of proteins appeared to be affected, predominantly in schizophrenia. ApoL appears to be one of a number of apolipoproteins that are altered in the CNS from subjects with psychiatric illness [48] . Focusing on studies using postmortem CNS, there is now evidence to show that levels of apoD [49, 50] and apoE [51] are altered in the CNS from subjects with schizophrenia. Given that apolipoproteins modulate different signal transduction pathways [52, 53] it is clear that changes in multiple apolipoproteins will have many diverse outcomes that could cause the symptoms of schizophrenia. In addition, at least in the case of apoD [54] and apoE [51] , levels of apolipoproteins are altered by treatments with antipsychotic drugs. This raises the possibility that changing the levels of apolipoproteins in the CNS of subjects with schizophrenia may be a mechanism that provides therapeutic benefits.
Altered Expression of Myelination Proteins in Schizophrenia: A Focus on Neuregulin 1 -erbB3 Signalling
The same study that identified an increase in RGS 7 expression in schizophrenia highlighted changes in the expression of genes related to myelination as being particularly affected in schizophrenia [29] . The expression of 6 genes associated with myelination (myelin and lymphocyte protein (MAL), 2', 3'-cyclic nucleotide 3'-phosphodiesterase, myelin associated glycoprotein (MAG), transferin, gelsolin and neuregulin receptor Her 3 (ErbB3)) were all decreased in the tissue from subjects with schizophrenia. Another microarray study in the temporal cortex has also shown significant decreases in myelination related genes (ErbB3, MAG and plasmolipin (PLLP)) in schizophrenia [30] . A third study has highlighted changes in the expression of myelination proteins in the dorsolateral prefrontal cortex in subjects with psychiatric disease [31] in reporting marked decreases in the expression of oligodendrocyte-specific protein (CLDN11), myelin oligodendrocyte glycoprotein (MOG) and, notably, ErbB3 in schizophrenia and bipolar disorder. Thus a number of studies suggest that changes in myelination related proteins may be widespread throughout the CNS of subjects with schizophrenia and that these changes may not be disease specific in that they are present in bipolar disorder.
A Model of Schizophrenia
It is clear that high-throughput screening of gene expression has provided exciting new data on genes and processes that are affected in schizophrenia. The question is whether these data can be incorporated into a cohesive model to describe some of the biological processes that become deranged to produce some of the symptoms of schizophrenia? With regards to the presynaptic proteins SNAP 25, SNAP 23, synaptophysin, NSF and synapsin II, it is relatively easy to propose how changes in these proteins could interact to cause significant disruption to CNS function. Synapsins are known to bind to each other and actin filaments to change the levels of vesicle clustering [55] (Fig. 2) . Disrupted synapsin function results in a reduction in the reserve pool of vesicles and hence decreases in the potential for vesicle fusion to the synaptic membrane with resulting neurotransmitter discharge. SNAP 25 [56] and SNAP 23 [57] are both membrane components of the SNARE complex, comprised of SNAP-25/23, syntaxin and vesicle associated membrane protein (VAMP), which facilitates vesicle docking to cell membrane. Abnormalities in this process would directly affect neurotransmitter release into the synapse. Synaptophysin is a vesicular membrane protein that interacts with VAMP protein to prevent the formation of the SNARE complex [58] whilst NSF acts to disassemble SNARE complexes [55] . Hence any or all of the changes in expression of these presynaptic proteins, identified using microarrays, would result in disruption of neurotransmitter release that could clearly be central to the pathology of schizophrenia.
One finding reproduced across some microarray studies is the decrease in the expression of ErbB3 in postmortem CNS [29] [30] [31] . These data are part of a growing body of evidence that implicate the neuregulin 1 -erbB signaling in the pathology of schizophrenia (For review see [32] ). Importantly, the neuregulin 1 -erbB signaling pathway has been shown to affect neuronal migration and neuronal specification, as well as the regulation of acetylcholine, GABA A and glutamate expression. Significantly, abnormalities of acetylcholine [33] , GABA A [34] and glutamate [35] have all been reported in postmortem CNS from subjects with schizophrenia. Therefore, it is possible that these hitherto apparently unconnected changes are all due to changes in the actions of the neuregulin 1 -erbB signaling pathway (Fig. 2) .
The recent demonstration that neuregulin 1 expression is not greatly altered in the dorsolateral prefrontal cortex of subjects with schizophrenia [36] suggests that the changes in the signaling pathway may not result from changes in levels of neuregulin 1. However, conflicting data as to whether [37] [38] [39] [40] [41] [42] or not [43] [44] [45] genotypes of the neuregulin 1 gene confer an increased risk of schizophrenia mean that further studies of the role of the protein in schizophrenia are warranted. Given that the increased risk to schizophrenia associated with the neuregulin 1 gene may vary with ethnicity [46] , it may be necessary to study isoform specific gene expression [32] in different ethnic populations to better understand the role of the protein in schizophrenia.
There is a potential link between the changes in the expression of presynaptic proteins and RGS 4 in the CNS of subjects with schizophrenia as it has been shown that synapsin Ia has the capacity to regulate the activity of RGS 4 [28] . It is still not clear whether regulation of RGS 4 activity is a general property of the synapsins or whether changes in the activity of RGS 4 may affect levels of expression of that protein and so this link remains a "long bow" from which to draw firm conclusions. It remains possible that changes in the expression of RGS 4 could be related to a particular genotype being over abundant in subjects with schizophrenia. However, it should be noted that levels of RGS 4 have been shown to be modulated via dopamine receptors [28, 59] and serotonin levels [60] . Therefore a simpler explanation regarding the change in RGS 4 expression in schizophrenia is that such changes are reflective of altered dopaminergic and serotonergic states, which have long been postulated to be central to the pathology of schizophrenia [61] .
Further analysis of proteins differentially expressed in the hippocampus of subjects with schizophrenia identified two proteins (T-complex protein 1 and collapsin response mediator protein-2) that were increased in tissue from subjects with the disorder whilst manganese superoxide dismutase was decreased [67] . Whilst these two studies only visualised 549 proteins between each group they acted as a proof of principal that 2D electrophoresis could provide new information on proteins altered in postmortem CNS from subjects with schizophrenia.
A more recent study which examined protein expression in cortical samples from 10 schizophrenic subjects and 10 control subjects reported that, of the 1256 proteins that could be matched across all gels, 215 were differentially expressed in tissue from subjects with schizophrenia [68] . The changed proteins suggested in this study were detailed in a follow up study where it was suggested that compromised brain metabolism and oxidative stress are critical to the pathology of schizophrenia [69] . This was based on the finding that 40 proteins found to be altered in the cortex of subjects with schizophrenia were associated with the mitochondria (n = 26), peroxisomes (n = 3) and/or oxidative stress (n = 26), some proteins being catogorised in more than one functional group. Significantly, in this study the levels of malate dehydrogenase 1, NAD soluble was decreased in tissue from subjects with schizophrenia, a finding that adds to a microarray study reporting decreased expression of that gene in the cortex from subjects with the disorder [12] . By contrast, levels of NSF protein were found to be increased in schizophrenia in this study even though the expression of the protein was reported as decreased in the first microarray study [16] . These data highlight the need for caution in extrapolating data from mRNA studies to outcomes at the protein level but reinforce the idea that studies of the human proteome will strengthen studies of gene expression in schizophrenia.
There appears to be no clear link between the neuregulin 1 -erbB signal transduction pathways and the expression of presynaptic proteins, RGS 4 or apolipoproteins. By contrast, there are strong data to link the activity of neuregulin 1 to expression levels of the NMDA, GABA A [32] and muscarinic [62] receptors. As there is clear evidence demonstrating changes in the levels of these receptors in postmortem CNS from subjects with schizophrenia [33, [63] [64] [65] , it could be postulated that changes in neuregulin-1 activity may contribute to the symptoms of schizophrenia by affecting receptor density and thus function. Furthermore, it remains possible that a combination of neuregulin influenced expression of critical neurotransmitter receptors, in combination with abnormal prevailing neurotransmitter levels due to changed presynaptic functioning (Fig. 2) , could be the core pathology of schizophrenia.
HIGH-THROUGHPUT SCREENING OF PROTEIN EXPRESSION IN SCHIZOPHRENIA
Another significant study of the human proteome is one using tissue from the Stanley Foundation collection which reported results in tissue from subjects with schizophrenia, bipolar disorder and major depression [70] . This study matched 217 spots across the 89 2D gels required to examine all samples of frontal cortex and showed that the intensity of 8 spots differed in various psychiatric illnesses. Significantly, no proteins were identified as changed only in tissue from subjects with schizophrenia. Dihydropyramidaserelated protein 2 was found to be decreased, whilst fructosebiphosphate aldolase was shown to be increased in all psychiatric disorders. In addition, two isoforms of glial fibrillary protein were shown to be decreased in schizophrenia and major depression. This study is important as it suggests there will be significant overlap in proteins that are affected by the pathologies of different psychiatric illnesses.
It is clear that high-throughput screening of gene expression has opened up new vistas on the potential causes of schizophrenia. However, one bottleneck in the process of assessing the outcomes from altered gene expression is the need to determine whether altered levels of mRNA in tissue correspond to changes in the level of the encoded protein.
One potential approach to resolving this issue is to use highthroughput screening of the proteome, the methodology capable of this task is 2D electrophoresis [4] .
The first attempt to combine 2D electrophoresis and postmortem CNS from subjects with schizophrenia was a study that compared changes in protein expression in the hippocampus from subjects with the disorder to tissue from control subjects and subjects with Alzheimer's disease [66] . In this study 16 proteins (8 increased and 8 decreased) were found to be present at different concentrations in the hippocampus from subjects with schizophrenia. The first protein fully characterized in the study, which was decreased in the hippocampus from subjects with schizophrenia and Alzheimer's disease, was diazepam binding inhibitor. Diazepam binding inhibitor regulates the binding characteristics of the GABA A receptor and therefore this study reinforced the potential role for that receptor in the pathology of schizophrenia.
POTENTIAL COMPLICATING FACTORS IN THE STUDY OF SCHIZOPHRENIA
In considering data from high-throughput screening of tissue from subjects with schizophrenia, it is necessary to acknowledge the impact of confounding factors in the analyses of results from such studies. Most importantly, it is widely accepted that schizophrenia is a syndrome and not a single illness. Using symptom cluster analysis it has been suggested that the syndrome of schizophrenia may include at least two [71] or more [72] disorders. Thus, rather than trying to incorporate the findings from high-throughput screening into a single model, it could be postulated that the three strong potential candidates genes emerging from microarray studies (presynaptic malfunction, RGS 4 and neuregulin-1) are reflecting the different pathologies of the illnesses within the syndrome. Challenging this hypothesis might require a consortium approach that allows the study of a large number of well characterized postmortem brains where cluster analysis may confirm earlier hypothesis made on similar approaches to symptom analysis. Another new frontier for postmortem CNS research is to unravel the contribution of epigenetics to the pathology of schizophrenia. Factors such as gene methylation can lead to gene imprinting where the expression of one of two alleles is favored. Imprinting is complex in that it can show tissue specificity [73] and in a complex organ such as the mammalian CNS, which is made up of cells with different lineages [74, 75] , will most likely occur within specific brain regions rather than uniformly across the entire CNS. Preliminary evidence of imprinting of serotonin receptors has already been uncovered in tissue from subjects with schizophrenia [76] ; this is likely to be the beginning of a new era in understanding how gene expression may be regulated. It would seem that targeted microarray studies [77] , or other high-throughput screening approaches [78] , will play an important role in elucidating the impact of epigenetic factors on the pathology of schizophrenia.
High-throughput screening using postmortem CNS from subjects with schizophrenia is rapidly evolving our concepts of the pathology of the disorder. Whilst some of these concepts, such as schizophrenia being a disorder of presynaptic function are not novel [79] , the use of microarrays and other high-throughput screening tools will accelerate the gathering of data to underpin hypotheses on the genesis of the disorder. With the possibility of peripheral markers to aid in both diagnosis and therapeutic choices [80, 81] on the horizon, it seems likely that the outcomes from high-throughput screening technologies will soon be influencing treatment practices.
